Associations Between Social Determinants of Health and CKM Stages | Docwire News
Researchers examined whether the prevalence of cardiovascular-kidney-metabolic syndrome stages varies by social determinants of health (SDOH).
Researchers examined whether the prevalence of cardiovascular-kidney-metabolic syndrome stages varies by social determinants of health (SDOH).
AbstractAntegrade wiring (AW) is the prevailing chronic total occlusion (CTO) crossing technique. For proximal cap ambiguity, the Global CTO consensus group uses the “anatomy dictates…
The European Medicines Agency Committee for Medicinal Products for Human Use has recommended that durvalumab (Imfinzi, AstraZeneca) receive approval in the European Union.
Providers should employ counseling services, support groups, and educational programs that provide community and mental health resources for patients with breast cancer.
Dr. Georgia Vasilakis Tsatiris of The CardioNerds speaks to Dr. Kevin Alexander about the impact of ATTR-CM.
In clinical practice, we frequently encounter critical questions for which we lack solid evidence. Whether on rounds or in the clinic, we often make decisions…
Highlights •Genetic fate mapping has confirmed the existence of the TIMD4hiMHCIIhi macrophage subset, demonstrating that they were resident macrophages with minimal contribution from peripheral mon…
On behalf of the proposed American Board of Cardiovascular Medicine (ABCVM) and our Board of Directors, I wanted to provide an update on the status…
AbstractFemoral venous access is increasingly used by structural interventional cardiologists in procedures such as patent foramen ovale, atrial septal defect, and left atrial appendage closure,…
AbstractBackgroundPatients with lymphoma are at high risk for developing heart failure (HF) after autologous hematopoietic cell transplantation (HCT). More accurate risk determination pre-HCT may f…
Researchers are launching a new clinical trial that will evaluate the combination of the bispecific antibody glofitamab with the noncovalent BTK inhibitor pirtobrutinib in MCL.